Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
A team at Griffith University’s Institute for Glycomics in Australia has received $300,000 in funding from The Bourne Foundation, as well as a ... Read more
A combination of bevacizumab and Zejula (niraparib) is significantly better than Zejula alone at extending the time without disease progression in people ... Read more
Analysis of cells in the fallopian tube, from which most ovarian cancers develop, can help classify ovarian cancer subtypes, with potential ... Read more
The first participant has been dosed in a Phase 1 clinical trial evaluating Tmunity Therapeutics‘ CAR T-cell therapy, CART-TnMUC1, in people ... Read more
ImmunoGen is planning to open an open-label, pivotal clinical trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer patients with high levels of ... Read more
Women who require assisted reproductive technology to become mothers are not more likely to develop ovarian cancer, except for those with ... Read more
Taking Zejula (niraparib) as a maintenance therapy may increase time without symptoms or toxicities from treatment in women with recurrent ovarian ... Read more
